Sign up to save your podcasts
Or
Share ASH Lymphoma 2024 Highlights - POLARIX Update, inMIND, TRIANGLE, ENRICH with Dr. Pallawi Torka
Share to email
Share to Facebook
Share to X
Share to email
Share to Facebook
Share to X
Or
ASH Lymphoma 2024 Highlights - POLARIX Update, inMIND, TRIANGLE, ENRICH with Dr. Pallawi Torka
Welcome to another episode of the Oncology Brothers podcast! In this episode, hosts Drs. Rahul and Rohit Gosain are joined by Dr. Pallawi Torka from Memorial Sloan Kettering Cancer Center to discuss the latest highlights from ASH 2024, focusing on key studies in lymphoma.
In this episode, we dive into:
• POLARIX Study: An update on the POLARIX trial, exploring the use of Polatuzumab in frontline diffuse large B-cell lymphoma (DLBCL) and its impact on progression-free survival (PFS).
• inMIND Study: A look at the promising results of the inMIND study, which evaluates the combination of Tafasitamab with Lenalidomide and Rituximab in the second-line setting for follicular lymphoma.
• Triangle Study: Insights into the evolving role of transplant in mantle cell lymphoma and the implications of BTK inhibitors in treatment.
• ENRICH Study: Discussion on the potential of Ibrutinib combined with Rituximab in the first-line setting and its comparison to traditional chemoimmunotherapy.
Join us as we unpack these practice-changing studies, discuss their implications for clinical practice, and share insights on managing side effects associated with new therapies.
Follow us on social media:
• X/Twitter: https://twitter.com/oncbrothers
• Instagram: https://www.instagram.com/oncbrothers
Don't forget to like, subscribe, and hit the notification bell for more updates on the latest in oncology research and practice!
#OncologyBrothers #ASH2024 #Lymphoma #CancerResearch #Podcast
View all episodes
By Oncology Brothers
4.8
3939 ratings
Welcome to another episode of the Oncology Brothers podcast! In this episode, hosts Drs. Rahul and Rohit Gosain are joined by Dr. Pallawi Torka from Memorial Sloan Kettering Cancer Center to discuss the latest highlights from ASH 2024, focusing on key studies in lymphoma.
In this episode, we dive into:
• POLARIX Study: An update on the POLARIX trial, exploring the use of Polatuzumab in frontline diffuse large B-cell lymphoma (DLBCL) and its impact on progression-free survival (PFS).
• inMIND Study: A look at the promising results of the inMIND study, which evaluates the combination of Tafasitamab with Lenalidomide and Rituximab in the second-line setting for follicular lymphoma.
• Triangle Study: Insights into the evolving role of transplant in mantle cell lymphoma and the implications of BTK inhibitors in treatment.
• ENRICH Study: Discussion on the potential of Ibrutinib combined with Rituximab in the first-line setting and its comparison to traditional chemoimmunotherapy.
Join us as we unpack these practice-changing studies, discuss their implications for clinical practice, and share insights on managing side effects associated with new therapies.
Follow us on social media:
• X/Twitter: https://twitter.com/oncbrothers
• Instagram: https://www.instagram.com/oncbrothers
Don't forget to like, subscribe, and hit the notification bell for more updates on the latest in oncology research and practice!
#OncologyBrothers #ASH2024 #Lymphoma #CancerResearch #Podcast
More shows like Oncology Brothers: Practice-Changing Cancer Discussions
View all
NEJM This Week
321 Listeners
Journal of Clinical Oncology (JCO) Podcast
42 Listeners
Research To Practice | Oncology Videos
111 Listeners
JAMA Clinical Reviews
502 Listeners
ASCO Daily News
60 Listeners
Core IM | Internal Medicine Podcast
1,110 Listeners
OncoPharm
182 Listeners
ASCO Guidelines
45 Listeners
OncLive® On Air
22 Listeners
Harrison's PodClass: Internal Medicine Cases and Board Prep
360 Listeners
Lung Cancer Considered
28 Listeners
The Passive Income MD Podcast
277 Listeners
Oncology Today with Dr Neil Love
60 Listeners
Two Onc Docs
181 Listeners
Blood Cancer Talks
48 Listeners